Compare RCBC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCBC | PHAT |
|---|---|---|
| Founded | 1963 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 736.3M | 590.6M |
| IPO Year | N/A | 2019 |
| Metric | RCBC | PHAT |
|---|---|---|
| Price | $55.72 | $7.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $56.00 | $20.45 |
| AVG Volume (30 Days) | 89.4K | ★ 1.2M |
| Earning Date | 10-23-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $80.58 |
| Revenue Next Year | $2.45 | $56.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $46.34 | $6.52 |
| 52 Week High | $56.71 | $18.31 |
| Indicator | RCBC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 73.20 | 39.36 |
| Support Level | $50.77 | $6.91 |
| Resistance Level | N/A | $9.74 |
| Average True Range (ATR) | 1.40 | 0.31 |
| MACD | 0.27 | 0.07 |
| Stochastic Oscillator | 85.99 | 54.59 |
River City Bank is a California state-chartered bank engaged in providing a range of banking services to individuals and businesses in California. The company's primary deposit products are checking, savings, and term certificate accounts, and its primary lending products are commercial real estate, commercial, agriculture, residential mortgage, and consumer loans. Substantially all loans are secured by specific items of collateral, including business assets, consumer assets, and commercial and residential real estate in the Western United States.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.